Exos Asset Management
REVBW icon

Exos Asset Management’s Revelation Biosciences Warrant REVBW Stock Holding History

Exos Asset Management’s Portfolio REVBW Stock Details REVBW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-19,000
Closed -$12K – 654
2021
Q2 		$12K Hold
19,000
– – 0.01% 752
2021
Q1 		$10K Buy
+19,000
New +$17.8K 0.01% 375

Other funds holding REVBW

Mangrove Partners
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Linden Advisors
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
Glazer Capital LLC
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Polar Asset Management Partners
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Owl Creek Asset Management
Owl Creek Asset Management New York $1.21B AUM 169.99% 1-Year Est. Return
CVI Holdings
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Yakira Capital Management
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
Boothbay Fund Management
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Ionic Capital Management
Ionic Capital Management New York $690M AUM 70.34% 1-Year Est. Return
Rivernorth Capital Management
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

Exos Asset Management's REVBW Position: Q3 2021 in Review

Exos Asset Management sold out of Revelation Biosciences Warrant (REVBW) in Q3 2021, closing a stake of 19,000 shares — an estimated $12K sold.

Exos Asset Management first reported a position in REVBW in Q1 2021 and held it in 2 quarters. The position peaked at $12K in Q2 2021. 18 funds tracked by Wall St. Rank hold REVBW as of Q3 2021.

  • Exos Asset Management reported no remaining Revelation Biosciences Warrant position as of Q3 2021 after selling out during the quarter.
  • Exos Asset Management sold 19,000 Revelation Biosciences Warrant shares in Q3 2021, an estimated $12K.
  • Exos Asset Management first reported a position in Revelation Biosciences Warrant in Q1 2021 and held it in 2 quarters.
  • Exos Asset Management's Revelation Biosciences Warrant position peaked at $12K in Q2 2021.
  • 18 funds tracked by Wall St. Rank held Revelation Biosciences Warrant as of Q3 2021.

Based on Exos Asset Management's 13F filing for Q3 2021, filed 25 Oct 2021.